Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX – Get Free Report) shares traded down 8.7% during trading on Monday . The stock traded as low as $1.01 and last traded at $1.05. 454,277 shares were traded during mid-day trading, a decline of 71% from the average session volume of 1,554,595 shares. The stock had previously closed at $1.15.
Salarius Pharmaceuticals Trading Down 8.7%
The company has a 50-day moving average of $0.78 and a 200-day moving average of $1.24. The firm has a market capitalization of $2.24 million, a price-to-earnings ratio of -0.22 and a beta of 0.40.
Salarius Pharmaceuticals (NASDAQ:SLRX – Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.40) by $1.37.
About Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.
Recommended Stories
- Five stocks we like better than Salarius Pharmaceuticals
- What is a support level?
- Microsoft Stock Holds Steady as AI Drives Workforce Shift
- What is a penny stock? A comprehensive guide
- D-Wave Goes International With South Korea Partnership
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?
Receive News & Ratings for Salarius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salarius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
